Nurix therapeutics announces participation in the 11th annual svb leerink global healthcare conference

San francisco, feb. 10, 2022 (globe newswire) -- nurix therapeutics, inc.  (nasdaq: nrix), a biopharmaceutical company developing targeted protein modulation drugs, today announced that arthur t. sands, m.d., ph.d., nurix's president and chief executive officer, will participate in a fireside chat at the 11th annual svb leerink global healthcare conference on thursday, february 17, 2022 at 3:40 pm et.
NRIX Ratings Summary
NRIX Quant Ranking